| 000 | 01417 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250517105228.0 | ||
| 264 | 0 | _c20160907 | |
| 008 | 201609s 0 0 eng d | ||
| 022 | _a0890-9091 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLevy, Benjamin P | |
| 245 | 0 | 0 |
_aAttacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors. _h[electronic resource] |
| 260 |
_bOncology (Williston Park, N.Y.) _cJul 2016 |
||
| 300 |
_a601-12 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xdrug therapy |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xgenetics |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xdrug effects |
| 650 | 0 | 4 |
_aErbB Receptors _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aRao, Parth | |
| 700 | 1 | _aBecker, Daniel J | |
| 700 | 1 | _aBecker, Kevin | |
| 773 | 0 |
_tOncology (Williston Park, N.Y.) _gvol. 30 _gno. 7 _gp. 601-12 |
|
| 999 |
_c26241237 _d26241237 |
||